Product image of Granisetron Dawa (Granisetron) supplied by GNH India

Granisetron Dawa

Active Ingredient:
Granisetron
Origin:
EU

Granisetron Dawa (Granisetron)

Granisetron Dawa is an oral medication containing the active ingredient granisetron, a selective 5‑HT3 receptor antagonist. Though the specific strength is not listed, the product is marketed in the European Union as a prescription‑only antiemetic. Granisetron Dawa works by blocking serotonin receptors in the central nervous system, helping to prevent nausea and vomiting associated with chemotherapy and postoperative recovery. It is classified under ATC code A04AA10.

Manufacturer / TM Owner

Dawa Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Granisetron Dawa is indicated for the prevention and treatment of nausea and vomiting in specific clinical settings.

  • Chemotherapy‑induced nausea and vomiting (CINV) in adult patients
  • Postoperative nausea and vomiting (PONV) following surgical procedures
  • Nausea associated with radiotherapy when used as part of an antiemetic regimen
  • Adjunct therapy for nausea in patients receiving highly emetogenic treatments
  • Nausea prophylaxis in patients receiving moderate‑emetic chemotherapy
  • Management of delayed‑onset nausea after chemotherapy

Side Effects

The safety profile of Granisetron Dawa reflects the typical effects observed with 5‑HT3 antagonists, ranging from mild, transient symptoms to rare serious events.

Common

  • Headache
  • Constipation or mild abdominal discomfort
  • Dizziness or light‑headedness
  • Fatigue or somnolence
  • Diarrhea
  • Dry mouth

Serious

  • Severe allergic reaction (anaphylaxis, rash, swelling)
  • Cardiac arrhythmias or QT prolongation
  • Serotonin syndrome when combined with serotonergic agents (rare)
  • Seizures (rare)

Precautions & Warnings

When prescribing Granisetron Dawa, clinicians should consider several precautionary measures to ensure safe use in diverse patient populations.

  • Assess for known hypersensitivity to granisetron or other 5‑HT3 antagonists
  • Use caution in patients with a history of cardiac conduction disorders or prolonged QT interval
  • Evaluate renal and hepatic function, as dose adjustments may be needed in severe impairment
  • Avoid use during pregnancy or lactation unless the potential benefit justifies the risk
  • Monitor for signs of serotonin syndrome when combined with serotonergic drugs
  • Consider age‑related dosing adjustments for elderly patients

Avoid Interactions

Granisetron Dawa may interact with other medications, influencing its efficacy or safety profile.

Avoid

  • Concomitant use with other 5‑HT3 antagonists (duplicate antiemetic therapy)
  • Strong CYP3A4 inhibitors that could increase granisetron plasma levels (e.g., ketoconazole, clarithromycin)

Use with caution

  • Serotonergic agents such as SSRIs, SNRIs, tramadol, or triptans (risk of serotonin syndrome)
  • Drugs that prolong QT interval (e.g., certain antiarrhythmics, antipsychotics)
  • Medications affecting electrolyte balance, especially potassium or magnesium, which can exacerbate cardiac effects

Frequently Asked Questions

Granisetron Dawa is an oral prescription medication that contains the active ingredient granisetron, a selective 5‑HT3 receptor antagonist used as an antiemetic.

It is commonly prescribed to prevent or treat nausea and vomiting caused by chemotherapy and by postoperative recovery.

Granisetron blocks serotonin (5‑HT3) receptors in the central nervous system and gastrointestinal tract, interrupting the signaling pathway that triggers nausea and vomiting.

No, Granisetron Dawa is a prescription‑only medication in the European Union.

Use during pregnancy is not recommended unless the potential benefit outweighs the risk, as safety data are limited.

Common side effects include headache, constipation, abdominal discomfort, dizziness, fatigue, diarrhea, and dry mouth.

Serious reactions, though rare, can include severe allergic responses, cardiac arrhythmias or QT prolongation, serotonin syndrome, and seizures.

Yes, using it together with another 5‑HT3 antagonist is generally avoided to prevent duplicate therapy and increased risk of side effects.

Granisetron may interact with strong CYP3A4 inhibitors, serotonergic agents (e.g., SSRIs, SNRIs, tramadol), and medications that prolong the QT interval.

Clinicians may monitor cardiac rhythm in patients with known QT issues, assess for allergic reactions, and watch for signs of serotonin syndrome when serotonergic drugs are co‑administered.

Dose adjustment may be considered in patients with severe hepatic or renal impairment, based on clinical judgment.

Granisetron Dawa is primarily approved for adult use; pediatric use should follow specific clinical guidelines and prescribing information.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Granisetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT